دورية أكاديمية

Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study

التفاصيل البيبلوغرافية
العنوان: Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
المؤلفون: Courtney Lawhn-Heath, Sue S. Yom, Chienying Liu, Javier E. Villanueva-Meyer, Maya Aslam, Raven Smith, Manpreet Narwal, Roxanna Juarez, Spencer C. Behr, Miguel Hernandez Pampaloni, Jason W. Chan, Christine M. Glastonbury, Thomas A. Hope, Robert R. Flavell
المصدر: EJNMMI Research, Vol 10, Iss 1, Pp 1-10 (2020)
بيانات النشر: SpringerOpen, 2020.
سنة النشر: 2020
المجموعة: LCC:Medical physics. Medical radiology. Nuclear medicine
مصطلحات موضوعية: Thyroid cancer, PSMA PET, PSMA therapy, Theranostics, PET/MRI, Medical physics. Medical radiology. Nuclear medicine, R895-920
الوصف: Abstract Background Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utility of [68Ga]Ga-PSMA-11 PET/MRI in thyroid cancer patients. Methods Eligible patients for this prospective pilot study were adults with a history of pathology-proven thyroid cancer who had abnormal radiotracer uptake on an 2-[18F]FDG PET and/or 131I scintigraphy performed in the 12 months prior to study enrollment. Patients underwent a [68Ga]Ga-PSMA-11 PET/MRI, and comparison was made to the prior qualifying 2-[18F]FDG PET CT/MRI for lesion location and relative intensity. Results Twelve patients underwent [68Ga]Ga-PSMA-11 PET/MRI, one of which was excluded from analysis due to debulking surgery prior to the PSMA PET. Of the remaining patients, 7/11 had differentiated disease (3 papillary, 2 follicular, 2 Hurthle cell) and 4/11 had dedifferentiated disease (2 poorly differentiated papillary, 2 anaplastic). Out of 43 lesions, 41 were visually 2-[18F]FDG positive (uptake greater than background, detection rate 95.3%) and 28 were PSMA positive (uptake greater than background, detection rate 65.1%). Uptake was heterogeneous between patients, and in some cases within patients. 3/11 patients (1 poorly differentiated papillary, 2 follicular) had PSMA uptake which was greater than FDG uptake. For the remaining 8 patients, 2-[18F]FDG uptake was greater than PSMA. Using one eligibility guideline in the prostate cancer literature for PSMA radioligand therapy (RLT), 8/11 could be considered eligible for possible future PSMA RLT. This was not predictable based on thyroid cancer subtype. Conclusions [68Ga]Ga-PSMA-11 PET demonstrated lower detection rate when compared to 2-[18F]FDG PET for thyroid cancer lesion visualization. Thyroid cancer subtype alone may not be sufficient to predict PSMA uptake, and radiotracer uptake may vary between patients and even within patients.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2191-219X
Relation: http://link.springer.com/article/10.1186/s13550-020-00720-3; https://doaj.org/toc/2191-219X
DOI: 10.1186/s13550-020-00720-3
URL الوصول: https://doaj.org/article/74f6d538c62e4f3fbf41cdcc2db22e29
رقم الأكسشن: edsdoj.74f6d538c62e4f3fbf41cdcc2db22e29
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:2191219X
DOI:10.1186/s13550-020-00720-3